TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 67.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,730 shares of the biopharmaceutical company’s stock after selling 15,884 shares during the period. SG Americas Securities LLC’s holdings in TG Therapeutics were worth $233,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. The Manufacturers Life Insurance Company raised its position in shares of TG Therapeutics by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock worth $1,435,000 after buying an additional 2,871 shares during the period. Creative Planning boosted its position in TG Therapeutics by 34.7% during the 2nd quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock valued at $833,000 after purchasing an additional 12,076 shares during the period. Handelsbanken Fonder AB lifted its position in TG Therapeutics by 22.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company’s stock valued at $1,167,000 after purchasing an additional 9,200 shares during the last quarter. Daymark Wealth Partners LLC boosted its position in shares of TG Therapeutics by 73.7% during the third quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 17,311 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new position in shares of TG Therapeutics during the third quarter valued at $239,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock worth $781,497 over the last three months. Company insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TGTX shares. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $33.50 on Friday. The firm’s 50-day moving average is $31.47 and its 200-day moving average is $26.83. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $5.21 billion, a price-to-earnings ratio of -334.97 and a beta of 2.26. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue was down 49.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.